Company intelligence / Profile preview

Resperin Corporation

Ownership: Private
Development stage: Other

Overview

Resperin Corporation is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and metabolic disorders. The company's lead program involves the development of intranasal insulin therapies designed to bypass the blood-brain barrier and target insulin resistance in the brain, a key factor in the progression of Alzheimer's disease. By utilizing a proprietary delivery system, Resperin aims to improve cognitive function and metabolic health in patients. The company has conducted several clinical trials to evaluate the safety and efficacy of its therapeutic candidates.

Therapeutic areas: EndocrinologyNeurology
Modalities: PeptidesSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Resperin Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resperin Corporation.

Explore the full profile